nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoxetate—ABCC3—Cisplatin—bone cancer	0.156	0.188	CbGbCtD
Gadoxetate—ABCC3—Doxorubicin—bone cancer	0.105	0.126	CbGbCtD
Gadoxetate—ABCC3—Methotrexate—bone cancer	0.101	0.122	CbGbCtD
Gadoxetate—SLCO1B3—Methotrexate—bone cancer	0.09	0.109	CbGbCtD
Gadoxetate—ABCC2—Carboplatin—bone cancer	0.083	0.1	CbGbCtD
Gadoxetate—ABCC4—Methotrexate—bone cancer	0.0774	0.0933	CbGbCtD
Gadoxetate—ABCC2—Cisplatin—bone cancer	0.0709	0.0855	CbGbCtD
Gadoxetate—SLCO1B1—Methotrexate—bone cancer	0.0524	0.0632	CbGbCtD
Gadoxetate—ABCC2—Doxorubicin—bone cancer	0.0475	0.0573	CbGbCtD
Gadoxetate—ABCC2—Methotrexate—bone cancer	0.0461	0.0555	CbGbCtD
Gadoxetate—ABCC3—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00294	0.0696	CbGpPWpGaD
Gadoxetate—ABCC3—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00275	0.0652	CbGpPWpGaD
Gadoxetate—ABCC4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00259	0.0613	CbGpPWpGaD
Gadoxetate—ABCC2—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00233	0.0552	CbGpPWpGaD
Gadoxetate—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00219	0.0519	CbGpPWpGaD
Gadoxetate—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00218	0.0517	CbGpPWpGaD
Gadoxetate—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00205	0.0486	CbGpPWpGaD
Gadoxetate—ABCC3—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00161	0.0381	CbGpPWpGaD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00158	0.0375	CbGpPWpGaD
Gadoxetate—ABCC4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00151	0.0358	CbGpPWpGaD
Gadoxetate—ABCC2—Irinotecan Pathway—CYP3A4—bone cancer	0.00149	0.0353	CbGpPWpGaD
Gadoxetate—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.0014	0.0331	CbGpPWpGaD
Gadoxetate—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00127	0.0302	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00125	0.0297	CbGpPWpGaD
Gadoxetate—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.0012	0.0284	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—DHFR—bone cancer	0.00112	0.0265	CbGpPWpGaD
Gadoxetate—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.00108	0.0257	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.00105	0.0249	CbGpPWpGaD
Gadoxetate—ABCC3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000969	0.023	CbGpPWpGaD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000923	0.0219	CbGpPWpGaD
Gadoxetate—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000768	0.0182	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000732	0.0174	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet degranulation—SPARC—bone cancer	0.000528	0.0125	CbGpPWpGaD
Gadoxetate—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000503	0.0119	CbGpPWpGaD
Gadoxetate—Oliguria—Doxorubicin—bone cancer	0.000466	0.00363	CcSEcCtD
Gadoxetate—Injection site reaction—Epirubicin—bone cancer	0.000461	0.00359	CcSEcCtD
Gadoxetate—Ulcer—Doxorubicin—bone cancer	0.000454	0.00353	CcSEcCtD
Gadoxetate—Creatinine increased—Doxorubicin—bone cancer	0.000451	0.00351	CcSEcCtD
Gadoxetate—Salivary hypersecretion—Epirubicin—bone cancer	0.000451	0.00351	CcSEcCtD
Gadoxetate—Connective tissue disorder—Cisplatin—bone cancer	0.000446	0.00347	CcSEcCtD
Gadoxetate—Fluid retention—Epirubicin—bone cancer	0.00044	0.00343	CcSEcCtD
Gadoxetate—Blood urea increased—Epirubicin—bone cancer	0.000438	0.00341	CcSEcCtD
Gadoxetate—Sepsis—Methotrexate—bone cancer	0.00043	0.00335	CcSEcCtD
Gadoxetate—Injection site reaction—Doxorubicin—bone cancer	0.000427	0.00332	CcSEcCtD
Gadoxetate—Rash maculo-papular—Epirubicin—bone cancer	0.000422	0.00328	CcSEcCtD
Gadoxetate—Flushing—Cisplatin—bone cancer	0.000421	0.00328	CcSEcCtD
Gadoxetate—Cardiac disorder—Cisplatin—bone cancer	0.000421	0.00328	CcSEcCtD
Gadoxetate—Salivary hypersecretion—Doxorubicin—bone cancer	0.000417	0.00325	CcSEcCtD
Gadoxetate—Immune system disorder—Cisplatin—bone cancer	0.00041	0.00319	CcSEcCtD
Gadoxetate—Mediastinal disorder—Cisplatin—bone cancer	0.000409	0.00318	CcSEcCtD
Gadoxetate—Fluid retention—Doxorubicin—bone cancer	0.000408	0.00317	CcSEcCtD
Gadoxetate—Arrhythmia—Cisplatin—bone cancer	0.000405	0.00315	CcSEcCtD
Gadoxetate—Blood urea increased—Doxorubicin—bone cancer	0.000405	0.00315	CcSEcCtD
Gadoxetate—Sepsis—Epirubicin—bone cancer	0.000403	0.00313	CcSEcCtD
Gadoxetate—Phlebitis—Epirubicin—bone cancer	0.000391	0.00304	CcSEcCtD
Gadoxetate—Rash maculo-papular—Doxorubicin—bone cancer	0.00039	0.00304	CcSEcCtD
Gadoxetate—Renal failure acute—Methotrexate—bone cancer	0.00039	0.00303	CcSEcCtD
Gadoxetate—Flatulence—Cisplatin—bone cancer	0.000389	0.00303	CcSEcCtD
Gadoxetate—Sepsis—Doxorubicin—bone cancer	0.000373	0.0029	CcSEcCtD
Gadoxetate—Vision blurred—Cisplatin—bone cancer	0.000372	0.0029	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Methotrexate—bone cancer	0.000372	0.00289	CcSEcCtD
Gadoxetate—Cardiac failure congestive—Epirubicin—bone cancer	0.000371	0.00289	CcSEcCtD
Gadoxetate—Tremor—Cisplatin—bone cancer	0.00037	0.00288	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Methotrexate—bone cancer	0.000367	0.00286	CcSEcCtD
Gadoxetate—Ill-defined disorder—Cisplatin—bone cancer	0.000366	0.00285	CcSEcCtD
Gadoxetate—Renal failure acute—Epirubicin—bone cancer	0.000365	0.00284	CcSEcCtD
Gadoxetate—Phlebitis—Doxorubicin—bone cancer	0.000362	0.00282	CcSEcCtD
Gadoxetate—Malaise—Cisplatin—bone cancer	0.000356	0.00277	CcSEcCtD
Gadoxetate—Renal impairment—Epirubicin—bone cancer	0.000354	0.00275	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Epirubicin—bone cancer	0.000348	0.00271	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Epirubicin—bone cancer	0.000344	0.00268	CcSEcCtD
Gadoxetate—Cardiac failure congestive—Doxorubicin—bone cancer	0.000344	0.00267	CcSEcCtD
Gadoxetate—Irritability—Methotrexate—bone cancer	0.000343	0.00267	CcSEcCtD
Gadoxetate—Convulsion—Cisplatin—bone cancer	0.000342	0.00266	CcSEcCtD
Gadoxetate—Renal failure acute—Doxorubicin—bone cancer	0.000338	0.00263	CcSEcCtD
Gadoxetate—Anxiety—Cisplatin—bone cancer	0.000335	0.00261	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000334	0.0026	CcSEcCtD
Gadoxetate—Discomfort—Cisplatin—bone cancer	0.000332	0.00259	CcSEcCtD
Gadoxetate—Renal impairment—Doxorubicin—bone cancer	0.000327	0.00255	CcSEcCtD
Gadoxetate—Face oedema—Epirubicin—bone cancer	0.000325	0.00253	CcSEcCtD
Gadoxetate—Oedema—Cisplatin—bone cancer	0.000322	0.00251	CcSEcCtD
Gadoxetate—Anaphylactic shock—Cisplatin—bone cancer	0.000322	0.00251	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000322	0.00251	CcSEcCtD
Gadoxetate—Infection—Cisplatin—bone cancer	0.00032	0.00249	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Doxorubicin—bone cancer	0.000318	0.00248	CcSEcCtD
Gadoxetate—Nervous system disorder—Cisplatin—bone cancer	0.000316	0.00246	CcSEcCtD
Gadoxetate—Blood creatinine increased—Epirubicin—bone cancer	0.000315	0.00246	CcSEcCtD
Gadoxetate—Tachycardia—Cisplatin—bone cancer	0.000315	0.00245	CcSEcCtD
Gadoxetate—Dehydration—Epirubicin—bone cancer	0.000313	0.00244	CcSEcCtD
Gadoxetate—Skin disorder—Cisplatin—bone cancer	0.000313	0.00244	CcSEcCtD
Gadoxetate—Hyperhidrosis—Cisplatin—bone cancer	0.000312	0.00243	CcSEcCtD
Gadoxetate—Anorexia—Cisplatin—bone cancer	0.000307	0.00239	CcSEcCtD
Gadoxetate—Hypokalaemia—Epirubicin—bone cancer	0.000306	0.00239	CcSEcCtD
Gadoxetate—Hypotension—Cisplatin—bone cancer	0.000301	0.00234	CcSEcCtD
Gadoxetate—Face oedema—Doxorubicin—bone cancer	0.000301	0.00234	CcSEcCtD
Gadoxetate—Abdominal distension—Epirubicin—bone cancer	0.000293	0.00228	CcSEcCtD
Gadoxetate—Blood creatinine increased—Doxorubicin—bone cancer	0.000292	0.00227	CcSEcCtD
Gadoxetate—Dysphagia—Epirubicin—bone cancer	0.000291	0.00227	CcSEcCtD
Gadoxetate—Dehydration—Doxorubicin—bone cancer	0.00029	0.00226	CcSEcCtD
Gadoxetate—Paraesthesia—Cisplatin—bone cancer	0.000289	0.00225	CcSEcCtD
Gadoxetate—Dyspnoea—Cisplatin—bone cancer	0.000287	0.00224	CcSEcCtD
Gadoxetate—Hypokalaemia—Doxorubicin—bone cancer	0.000284	0.00221	CcSEcCtD
Gadoxetate—Decreased appetite—Cisplatin—bone cancer	0.00028	0.00218	CcSEcCtD
Gadoxetate—Bronchitis—Epirubicin—bone cancer	0.00028	0.00218	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Cisplatin—bone cancer	0.000278	0.00217	CcSEcCtD
Gadoxetate—Renal failure—Methotrexate—bone cancer	0.000273	0.00212	CcSEcCtD
Gadoxetate—Abdominal distension—Doxorubicin—bone cancer	0.000271	0.00211	CcSEcCtD
Gadoxetate—Conjunctivitis—Methotrexate—bone cancer	0.00027	0.0021	CcSEcCtD
Gadoxetate—Dysphagia—Doxorubicin—bone cancer	0.000269	0.0021	CcSEcCtD
Gadoxetate—Feeling abnormal—Cisplatin—bone cancer	0.000266	0.00207	CcSEcCtD
Gadoxetate—Bronchitis—Doxorubicin—bone cancer	0.000259	0.00202	CcSEcCtD
Gadoxetate—Renal failure—Epirubicin—bone cancer	0.000255	0.00199	CcSEcCtD
Gadoxetate—Body temperature increased—Cisplatin—bone cancer	0.000255	0.00198	CcSEcCtD
Gadoxetate—Conjunctivitis—Epirubicin—bone cancer	0.000252	0.00196	CcSEcCtD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	0.000249	0.00591	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—TGFBR2—bone cancer	0.000246	0.00583	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—GSTP1—bone cancer	0.000246	0.00583	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Cisplatin—bone cancer	0.000237	0.00185	CcSEcCtD
Gadoxetate—Renal failure—Doxorubicin—bone cancer	0.000236	0.00184	CcSEcCtD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000234	0.00556	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000234	0.00555	CbGpPWpGaD
Gadoxetate—Rhinitis—Epirubicin—bone cancer	0.000234	0.00182	CcSEcCtD
Gadoxetate—Conjunctivitis—Doxorubicin—bone cancer	0.000233	0.00182	CcSEcCtD
Gadoxetate—Hypoaesthesia—Epirubicin—bone cancer	0.000232	0.0018	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000231	0.00548	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000231	0.00548	CbGpPWpGaD
Gadoxetate—Asthenia—Cisplatin—bone cancer	0.000231	0.0018	CcSEcCtD
Gadoxetate—Cardiac disorder—Methotrexate—bone cancer	0.000231	0.0018	CcSEcCtD
Gadoxetate—Connective tissue disorder—Epirubicin—bone cancer	0.000229	0.00178	CcSEcCtD
Gadoxetate—Angiopathy—Methotrexate—bone cancer	0.000226	0.00176	CcSEcCtD
Gadoxetate—Immune system disorder—Methotrexate—bone cancer	0.000225	0.00175	CcSEcCtD
Gadoxetate—Mediastinal disorder—Methotrexate—bone cancer	0.000224	0.00175	CcSEcCtD
Gadoxetate—Chills—Methotrexate—bone cancer	0.000223	0.00174	CcSEcCtD
Gadoxetate—Diarrhoea—Cisplatin—bone cancer	0.000221	0.00172	CcSEcCtD
Gadoxetate—Cardiac disorder—Epirubicin—bone cancer	0.000216	0.00168	CcSEcCtD
Gadoxetate—Flushing—Epirubicin—bone cancer	0.000216	0.00168	CcSEcCtD
Gadoxetate—Rhinitis—Doxorubicin—bone cancer	0.000216	0.00168	CcSEcCtD
Gadoxetate—Hypoaesthesia—Doxorubicin—bone cancer	0.000214	0.00167	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000214	0.00508	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000214	0.00508	CbGpPWpGaD
Gadoxetate—Dysgeusia—Methotrexate—bone cancer	0.000212	0.00165	CcSEcCtD
Gadoxetate—Connective tissue disorder—Doxorubicin—bone cancer	0.000212	0.00165	CcSEcCtD
Gadoxetate—Angiopathy—Epirubicin—bone cancer	0.000211	0.00165	CcSEcCtD
Gadoxetate—Immune system disorder—Epirubicin—bone cancer	0.00021	0.00164	CcSEcCtD
Gadoxetate—Mediastinal disorder—Epirubicin—bone cancer	0.00021	0.00163	CcSEcCtD
Gadoxetate—Back pain—Methotrexate—bone cancer	0.00021	0.00163	CcSEcCtD
Gadoxetate—Chills—Epirubicin—bone cancer	0.000209	0.00163	CcSEcCtD
Gadoxetate—Arrhythmia—Epirubicin—bone cancer	0.000208	0.00162	CcSEcCtD
Gadoxetate—Vomiting—Cisplatin—bone cancer	0.000205	0.0016	CcSEcCtD
Gadoxetate—Vision blurred—Methotrexate—bone cancer	0.000204	0.00159	CcSEcCtD
Gadoxetate—Rash—Cisplatin—bone cancer	0.000203	0.00158	CcSEcCtD
Gadoxetate—Dermatitis—Cisplatin—bone cancer	0.000203	0.00158	CcSEcCtD
Gadoxetate—Ill-defined disorder—Methotrexate—bone cancer	0.000201	0.00157	CcSEcCtD
Gadoxetate—Flushing—Doxorubicin—bone cancer	0.0002	0.00156	CcSEcCtD
Gadoxetate—Cardiac disorder—Doxorubicin—bone cancer	0.0002	0.00156	CcSEcCtD
Gadoxetate—Flatulence—Epirubicin—bone cancer	0.0002	0.00156	CcSEcCtD
Gadoxetate—Dysgeusia—Epirubicin—bone cancer	0.000199	0.00155	CcSEcCtD
Gadoxetate—Back pain—Epirubicin—bone cancer	0.000196	0.00153	CcSEcCtD
Gadoxetate—Angiopathy—Doxorubicin—bone cancer	0.000196	0.00152	CcSEcCtD
Gadoxetate—Malaise—Methotrexate—bone cancer	0.000195	0.00152	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000195	0.00462	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000195	0.00462	CbGpPWpGaD
Gadoxetate—Immune system disorder—Doxorubicin—bone cancer	0.000195	0.00152	CcSEcCtD
Gadoxetate—Vertigo—Methotrexate—bone cancer	0.000195	0.00152	CcSEcCtD
Gadoxetate—Mediastinal disorder—Doxorubicin—bone cancer	0.000194	0.00151	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000194	0.0046	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000193	0.00459	CbGpPWpGaD
Gadoxetate—Chills—Doxorubicin—bone cancer	0.000193	0.00151	CcSEcCtD
Gadoxetate—Arrhythmia—Doxorubicin—bone cancer	0.000193	0.0015	CcSEcCtD
Gadoxetate—Nausea—Cisplatin—bone cancer	0.000191	0.00149	CcSEcCtD
Gadoxetate—Vision blurred—Epirubicin—bone cancer	0.000191	0.00149	CcSEcCtD
Gadoxetate—Cough—Methotrexate—bone cancer	0.000189	0.00147	CcSEcCtD
Gadoxetate—Ill-defined disorder—Epirubicin—bone cancer	0.000188	0.00146	CcSEcCtD
Gadoxetate—Convulsion—Methotrexate—bone cancer	0.000188	0.00146	CcSEcCtD
Gadoxetate—Agitation—Epirubicin—bone cancer	0.000186	0.00145	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000185	0.00439	CbGpPWpGaD
Gadoxetate—Flatulence—Doxorubicin—bone cancer	0.000185	0.00144	CcSEcCtD
Gadoxetate—Chest pain—Methotrexate—bone cancer	0.000185	0.00144	CcSEcCtD
Gadoxetate—Dysgeusia—Doxorubicin—bone cancer	0.000184	0.00143	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000183	0.00143	CcSEcCtD
Gadoxetate—Malaise—Epirubicin—bone cancer	0.000183	0.00142	CcSEcCtD
Gadoxetate—Discomfort—Methotrexate—bone cancer	0.000182	0.00142	CcSEcCtD
Gadoxetate—Vertigo—Epirubicin—bone cancer	0.000182	0.00142	CcSEcCtD
Gadoxetate—Syncope—Epirubicin—bone cancer	0.000182	0.00142	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000182	0.00431	CbGpPWpGaD
Gadoxetate—Back pain—Doxorubicin—bone cancer	0.000182	0.00141	CcSEcCtD
Gadoxetate—Palpitations—Epirubicin—bone cancer	0.000179	0.0014	CcSEcCtD
Gadoxetate—Loss of consciousness—Epirubicin—bone cancer	0.000178	0.00139	CcSEcCtD
Gadoxetate—Cough—Epirubicin—bone cancer	0.000177	0.00138	CcSEcCtD
Gadoxetate—Anaphylactic shock—Methotrexate—bone cancer	0.000177	0.00138	CcSEcCtD
Gadoxetate—Vision blurred—Doxorubicin—bone cancer	0.000177	0.00138	CcSEcCtD
Gadoxetate—Convulsion—Epirubicin—bone cancer	0.000176	0.00137	CcSEcCtD
Gadoxetate—Infection—Methotrexate—bone cancer	0.000176	0.00137	CcSEcCtD
Gadoxetate—Ill-defined disorder—Doxorubicin—bone cancer	0.000174	0.00136	CcSEcCtD
Gadoxetate—Nervous system disorder—Methotrexate—bone cancer	0.000173	0.00135	CcSEcCtD
Gadoxetate—Chest pain—Epirubicin—bone cancer	0.000173	0.00134	CcSEcCtD
Gadoxetate—Agitation—Doxorubicin—bone cancer	0.000172	0.00134	CcSEcCtD
Gadoxetate—Anxiety—Epirubicin—bone cancer	0.000172	0.00134	CcSEcCtD
Gadoxetate—Skin disorder—Methotrexate—bone cancer	0.000172	0.00134	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000171	0.00133	CcSEcCtD
Gadoxetate—Hyperhidrosis—Methotrexate—bone cancer	0.000171	0.00133	CcSEcCtD
Gadoxetate—Discomfort—Epirubicin—bone cancer	0.000171	0.00133	CcSEcCtD
Gadoxetate—Malaise—Doxorubicin—bone cancer	0.000169	0.00132	CcSEcCtD
Gadoxetate—Dry mouth—Epirubicin—bone cancer	0.000169	0.00131	CcSEcCtD
Gadoxetate—Vertigo—Doxorubicin—bone cancer	0.000169	0.00131	CcSEcCtD
Gadoxetate—Anorexia—Methotrexate—bone cancer	0.000169	0.00131	CcSEcCtD
Gadoxetate—Syncope—Doxorubicin—bone cancer	0.000168	0.00131	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—NDUFA12—bone cancer	0.000168	0.00397	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000167	0.00396	CbGpPWpGaD
Gadoxetate—Palpitations—Doxorubicin—bone cancer	0.000166	0.00129	CcSEcCtD
Gadoxetate—Oedema—Epirubicin—bone cancer	0.000166	0.00129	CcSEcCtD
Gadoxetate—Anaphylactic shock—Epirubicin—bone cancer	0.000166	0.00129	CcSEcCtD
Gadoxetate—Hypotension—Methotrexate—bone cancer	0.000165	0.00129	CcSEcCtD
Gadoxetate—Loss of consciousness—Doxorubicin—bone cancer	0.000165	0.00128	CcSEcCtD
Gadoxetate—Infection—Epirubicin—bone cancer	0.000164	0.00128	CcSEcCtD
Gadoxetate—Cough—Doxorubicin—bone cancer	0.000164	0.00127	CcSEcCtD
Gadoxetate—Shock—Epirubicin—bone cancer	0.000163	0.00127	CcSEcCtD
Gadoxetate—Convulsion—Doxorubicin—bone cancer	0.000163	0.00127	CcSEcCtD
Gadoxetate—Nervous system disorder—Epirubicin—bone cancer	0.000162	0.00126	CcSEcCtD
Gadoxetate—Tachycardia—Epirubicin—bone cancer	0.000162	0.00126	CcSEcCtD
Gadoxetate—Skin disorder—Epirubicin—bone cancer	0.000161	0.00125	CcSEcCtD
Gadoxetate—Hyperhidrosis—Epirubicin—bone cancer	0.00016	0.00125	CcSEcCtD
Gadoxetate—Chest pain—Doxorubicin—bone cancer	0.00016	0.00124	CcSEcCtD
Gadoxetate—Anxiety—Doxorubicin—bone cancer	0.000159	0.00124	CcSEcCtD
Gadoxetate—Paraesthesia—Methotrexate—bone cancer	0.000159	0.00124	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000159	0.00124	CcSEcCtD
Gadoxetate—Discomfort—Doxorubicin—bone cancer	0.000158	0.00123	CcSEcCtD
Gadoxetate—Anorexia—Epirubicin—bone cancer	0.000158	0.00123	CcSEcCtD
Gadoxetate—Dyspnoea—Methotrexate—bone cancer	0.000158	0.00123	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000157	0.00372	CbGpPWpGaD
Gadoxetate—Dry mouth—Doxorubicin—bone cancer	0.000156	0.00122	CcSEcCtD
Gadoxetate—Hypotension—Epirubicin—bone cancer	0.000155	0.0012	CcSEcCtD
Gadoxetate—Decreased appetite—Methotrexate—bone cancer	0.000154	0.0012	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000153	0.00364	CbGpPWpGaD
Gadoxetate—Oedema—Doxorubicin—bone cancer	0.000153	0.00119	CcSEcCtD
Gadoxetate—Anaphylactic shock—Doxorubicin—bone cancer	0.000153	0.00119	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000153	0.00119	CcSEcCtD
Gadoxetate—Fatigue—Methotrexate—bone cancer	0.000152	0.00119	CcSEcCtD
Gadoxetate—Infection—Doxorubicin—bone cancer	0.000152	0.00118	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—NDUFA12—bone cancer	0.000151	0.00359	CbGpPWpGaD
Gadoxetate—Shock—Doxorubicin—bone cancer	0.000151	0.00117	CcSEcCtD
Gadoxetate—Nervous system disorder—Doxorubicin—bone cancer	0.00015	0.00117	CcSEcCtD
Gadoxetate—Tachycardia—Doxorubicin—bone cancer	0.000149	0.00116	CcSEcCtD
Gadoxetate—Skin disorder—Doxorubicin—bone cancer	0.000149	0.00116	CcSEcCtD
Gadoxetate—Paraesthesia—Epirubicin—bone cancer	0.000149	0.00116	CcSEcCtD
Gadoxetate—Hyperhidrosis—Doxorubicin—bone cancer	0.000148	0.00115	CcSEcCtD
Gadoxetate—Dyspnoea—Epirubicin—bone cancer	0.000148	0.00115	CcSEcCtD
Gadoxetate—Anorexia—Doxorubicin—bone cancer	0.000146	0.00114	CcSEcCtD
Gadoxetate—Feeling abnormal—Methotrexate—bone cancer	0.000146	0.00113	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Methotrexate—bone cancer	0.000145	0.00113	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000144	0.00342	CbGpPWpGaD
Gadoxetate—Decreased appetite—Epirubicin—bone cancer	0.000144	0.00112	CcSEcCtD
Gadoxetate—Hypotension—Doxorubicin—bone cancer	0.000143	0.00111	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000143	0.00111	CcSEcCtD
Gadoxetate—Fatigue—Epirubicin—bone cancer	0.000143	0.00111	CcSEcCtD
Gadoxetate—Constipation—Epirubicin—bone cancer	0.000142	0.0011	CcSEcCtD
Gadoxetate—Urticaria—Methotrexate—bone cancer	0.000141	0.00109	CcSEcCtD
Gadoxetate—Abdominal pain—Methotrexate—bone cancer	0.00014	0.00109	CcSEcCtD
Gadoxetate—Body temperature increased—Methotrexate—bone cancer	0.00014	0.00109	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—NT5C3A—bone cancer	0.000139	0.00329	CbGpPWpGaD
Gadoxetate—Paraesthesia—Doxorubicin—bone cancer	0.000138	0.00107	CcSEcCtD
Gadoxetate—Dyspnoea—Doxorubicin—bone cancer	0.000137	0.00106	CcSEcCtD
Gadoxetate—Feeling abnormal—Epirubicin—bone cancer	0.000136	0.00106	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Epirubicin—bone cancer	0.000135	0.00105	CcSEcCtD
Gadoxetate—Decreased appetite—Doxorubicin—bone cancer	0.000133	0.00104	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000132	0.00314	CbGpPWpGaD
Gadoxetate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000132	0.00103	CcSEcCtD
Gadoxetate—Fatigue—Doxorubicin—bone cancer	0.000132	0.00103	CcSEcCtD
Gadoxetate—Urticaria—Epirubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Gadoxetate—Constipation—Doxorubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Gadoxetate—Abdominal pain—Epirubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Gadoxetate—Body temperature increased—Epirubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Gadoxetate—Hypersensitivity—Methotrexate—bone cancer	0.00013	0.00101	CcSEcCtD
Gadoxetate—Asthenia—Methotrexate—bone cancer	0.000127	0.000988	CcSEcCtD
Gadoxetate—Feeling abnormal—Doxorubicin—bone cancer	0.000126	0.000982	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—NT5C3A—bone cancer	0.000125	0.00297	CbGpPWpGaD
Gadoxetate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000125	0.000975	CcSEcCtD
Gadoxetate—Pruritus—Methotrexate—bone cancer	0.000125	0.000974	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000124	0.00295	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Epirubicin—bone cancer	0.000122	0.000949	CcSEcCtD
Gadoxetate—Urticaria—Doxorubicin—bone cancer	0.000122	0.000947	CcSEcCtD
Gadoxetate—Body temperature increased—Doxorubicin—bone cancer	0.000121	0.000942	CcSEcCtD
Gadoxetate—Abdominal pain—Doxorubicin—bone cancer	0.000121	0.000942	CcSEcCtD
Gadoxetate—Diarrhoea—Methotrexate—bone cancer	0.000121	0.000942	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—SPARC—bone cancer	0.000121	0.00286	CbGpPWpGaD
Gadoxetate—Asthenia—Epirubicin—bone cancer	0.000119	0.000924	CcSEcCtD
Gadoxetate—Pruritus—Epirubicin—bone cancer	0.000117	0.000912	CcSEcCtD
Gadoxetate—Dizziness—Methotrexate—bone cancer	0.000117	0.00091	CcSEcCtD
Gadoxetate—Diarrhoea—Epirubicin—bone cancer	0.000113	0.000882	CcSEcCtD
Gadoxetate—Hypersensitivity—Doxorubicin—bone cancer	0.000113	0.000878	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism—NDUFA12—bone cancer	0.000113	0.00267	CbGpPWpGaD
Gadoxetate—Vomiting—Methotrexate—bone cancer	0.000112	0.000875	CcSEcCtD
Gadoxetate—Rash—Methotrexate—bone cancer	0.000112	0.000868	CcSEcCtD
Gadoxetate—Dermatitis—Methotrexate—bone cancer	0.000111	0.000867	CcSEcCtD
Gadoxetate—Headache—Methotrexate—bone cancer	0.000111	0.000862	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—GNA11—bone cancer	0.00011	0.00262	CbGpPWpGaD
Gadoxetate—Asthenia—Doxorubicin—bone cancer	0.00011	0.000855	CcSEcCtD
Gadoxetate—Dizziness—Epirubicin—bone cancer	0.000109	0.000852	CcSEcCtD
Gadoxetate—Pruritus—Doxorubicin—bone cancer	0.000108	0.000843	CcSEcCtD
Gadoxetate—Vomiting—Epirubicin—bone cancer	0.000105	0.000819	CcSEcCtD
Gadoxetate—Nausea—Methotrexate—bone cancer	0.000105	0.000818	CcSEcCtD
Gadoxetate—Diarrhoea—Doxorubicin—bone cancer	0.000105	0.000816	CcSEcCtD
Gadoxetate—Rash—Epirubicin—bone cancer	0.000104	0.000812	CcSEcCtD
Gadoxetate—Dermatitis—Epirubicin—bone cancer	0.000104	0.000812	CcSEcCtD
Gadoxetate—Headache—Epirubicin—bone cancer	0.000104	0.000807	CcSEcCtD
Gadoxetate—Dizziness—Doxorubicin—bone cancer	0.000101	0.000788	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—IL3—bone cancer	0.0001	0.00237	CbGpPWpGaD
Gadoxetate—Nausea—Epirubicin—bone cancer	9.83e-05	0.000765	CcSEcCtD
Gadoxetate—Vomiting—Doxorubicin—bone cancer	9.74e-05	0.000758	CcSEcCtD
Gadoxetate—Rash—Doxorubicin—bone cancer	9.66e-05	0.000752	CcSEcCtD
Gadoxetate—Dermatitis—Doxorubicin—bone cancer	9.65e-05	0.000751	CcSEcCtD
Gadoxetate—Headache—Doxorubicin—bone cancer	9.59e-05	0.000747	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism—NT5C3A—bone cancer	9.33e-05	0.00221	CbGpPWpGaD
Gadoxetate—Nausea—Doxorubicin—bone cancer	9.1e-05	0.000708	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—PLAU—bone cancer	6.56e-05	0.00156	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ENO2—bone cancer	6.08e-05	0.00144	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—DHFR—bone cancer	5.64e-05	0.00134	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ENO2—bone cancer	5.49e-05	0.0013	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GNA11—bone cancer	5.27e-05	0.00125	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—DHFR—bone cancer	5.09e-05	0.00121	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP3A4—bone cancer	4.78e-05	0.00113	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GNA11—bone cancer	4.76e-05	0.00113	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.76e-05	0.00113	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP3A4—bone cancer	4.31e-05	0.00102	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.29e-05	0.00102	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTP1—bone cancer	4.09e-05	0.00097	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ENO2—bone cancer	4.09e-05	0.000969	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—DHFR—bone cancer	3.79e-05	0.000899	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTP1—bone cancer	3.69e-05	0.000875	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GNA11—bone cancer	3.54e-05	0.00084	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CYP3A4—bone cancer	3.21e-05	0.000762	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.2e-05	0.000758	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTP1—bone cancer	2.75e-05	0.000652	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—TP53—bone cancer	2.64e-05	0.000626	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTGS2—bone cancer	2.12e-05	0.000502	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTGS2—bone cancer	1.91e-05	0.000453	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTGS2—bone cancer	1.42e-05	0.000338	CbGpPWpGaD
